Selecta Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.11
- Today's High:
- $1.16
- Open Price:
- $1.12
- 52W Low:
- $0.9
- 52W High:
- $1.99
- Prev. Close:
- $1.12
- Volume:
- 434406
Company Statistics
- Market Cap.:
- $171.84 million
- Book Value:
- 0.427
- Revenue TTM:
- $48.69 million
- Operating Margin TTM:
- -96.76%
- Gross Profit TTM:
- $38.40 million
- Profit Margin:
- -71.98%
- Return on Assets TTM:
- -17.98%
- Return on Equity TTM:
- -45.21%
Company Profile
Selecta Biosciences Inc had its IPO on 2016-06-22 under the ticker symbol SELB.
The company operates in the Healthcare sector and Biotechnology industry. Selecta Biosciences Inc has a staff strength of 64 employees.
Stock update
Shares of Selecta Biosciences Inc opened at $1.12 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.11 - $1.16, and closed at $1.14.
This is a +1.79% increase from the previous day's closing price.
A total volume of 434,406 shares were traded at the close of the day’s session.
In the last one week, shares of Selecta Biosciences Inc have slipped by -7.32%.
Selecta Biosciences Inc's Key Ratios
Selecta Biosciences Inc has a market cap of $171.84 million, indicating a price to book ratio of 2.3611 and a price to sales ratio of 1.5437.
In the last 12-months Selecta Biosciences Inc’s revenue was $48.69 million with a gross profit of $38.40 million and an EBITDA of $-46741000. The EBITDA ratio measures Selecta Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Selecta Biosciences Inc’s operating margin was -96.76% while its return on assets stood at -17.98% with a return of equity of -45.21%.
In Q2, Selecta Biosciences Inc’s quarterly earnings growth was a positive 53.7% while revenue growth was a negative 86.6%.
Selecta Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 25.4453
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.28 per share while it has a forward price to earnings multiple of 25.4453 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Selecta Biosciences Inc’s profitability.
Selecta Biosciences Inc stock is trading at a EV to sales ratio of 0.7439 and a EV to EBITDA ratio of 2.0072. Its price to sales ratio in the trailing 12-months stood at 1.5437.
Selecta Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $139.51 million
- Total Liabilities
- $29.37 million
- Operating Cash Flow
- $28.11 million
- Capital Expenditure
- $12000
- Dividend Payout Ratio
- 0%
Selecta Biosciences Inc ended 2024 with $139.51 million in total assets and $0 in total liabilities. Its intangible assets were valued at $139.51 million while shareholder equity stood at $65.45 million.
Selecta Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $29.37 million in other current liabilities, 15000.00 in common stock, $-427987000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $112.03 million and cash and short-term investments were $112.03 million. The company’s total short-term debt was $11,964,000 while long-term debt stood at $13.79 million.
Selecta Biosciences Inc’s total current assets stands at $122.73 million while long-term investments were $2.00 million and short-term investments were $0.00. Its net receivables were $6.44 million compared to accounts payable of $267000.00 and inventory worth $0.
In 2024, Selecta Biosciences Inc's operating cash flow was $28.11 million while its capital expenditure stood at $12000.
Comparatively, Selecta Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.14
- 52-Week High
- $1.99
- 52-Week Low
- $0.9
- Analyst Target Price
- $4.67
Selecta Biosciences Inc stock is currently trading at $1.14 per share. It touched a 52-week high of $1.99 and a 52-week low of $1.99. Analysts tracking the stock have a 12-month average target price of $4.67.
Its 50-day moving average was $1.12 and 200-day moving average was $1.29 The short ratio stood at 19.89 indicating a short percent outstanding of 0%.
Around 2505.6% of the company’s stock are held by insiders while 4777.6% are held by institutions.
Frequently Asked Questions About Selecta Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.